Denali Therapeutics (NASDAQ:DNLI) Releases Earnings Results, Beats Estimates By $0.01 EPS

Denali Therapeutics (NASDAQ:DNLI) posted its earnings results on Tuesday. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.01, Briefing.com reports. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same quarter in the previous year, the business earned ($0.80) earnings per share.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $16.85 on Wednesday. The business has a 50 day simple moving average of $18.82 and a two-hundred day simple moving average of $18.84. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.31. The firm has a market capitalization of $2.40 billion, a PE ratio of -15.60 and a beta of 1.39.

Insider Buying and Selling

In other news, insider Carole Ho sold 2,784 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total transaction of $48,135.36. Following the completion of the sale, the insider now directly owns 145,010 shares of the company’s stock, valued at $2,507,222.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Carole Ho sold 2,784 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total value of $48,135.36. Following the completion of the sale, the insider now owns 145,010 shares in the company, valued at $2,507,222.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $18.37, for a total value of $30,604.42. Following the sale, the director now directly owns 121,375 shares of the company’s stock, valued at $2,229,658.75. The disclosure for this sale can be found here. In the last three months, insiders sold 110,955 shares of company stock valued at $2,218,802. Insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. The Goldman Sachs Group cut their price target on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, February 29th. UBS Group decreased their price target on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th. Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Denali Therapeutics in a research note on Wednesday, February 28th. Finally, HC Wainwright lowered their price target on shares of Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Denali Therapeutics has an average rating of “Buy” and an average price target of $41.22.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.